Who
Martin H. Huber Jr.
Director
Company insider
Files Form 4 as: Director, Actuate Therapeutics; Director, Syndax Pharmaceuticals; President, CEO, Mersana Therapeutics; President and Head of R&D, Xilio Therapeutics; SVP & Chief Medical Officer, Tesaro.
In numbers
- Trades disclosed
- 125
- Buys
- 1
- Sells
- 12
- Bought
- $45K
- Sold
- $850K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 21 Sep 2015
- Last trade
- 21 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana TherapeuticsBiotechnology | SEC FORM 4 Code U | —9,573 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —734 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —179 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,121 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —27,878 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —364 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —497 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,467 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —13,340 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,328 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,256 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,938 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —26,713 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,938 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,713 | filing |
| 6 Jan 2026filed 6 Jan 2026 | Mersana Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,923 | filing |
News
Syndax Pharmaceuticals (SNDX) – Analysts' Recent Ratings ChangesSNDX · dailypolitical.com · 19 Oct 2026Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Martin H. Huber Jr.; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.